Adlyxin (lixisenatide) / Zealand Pharma, Sanofi, Royalty - LARVOL DELTA

CARDIOVASCULAR OUTCOMES AND MORTALITY ASSOCIATED WITH GLP-1 RECEPTOR AGONISTS IN INFLAMMATORY MYOSITIS AND NECROTIZING MYOPATHY: A RETROSPECTIVE COHORT STUDY (EULAR 2025) - "The cohort with GLP-1 RA use (n = 3,066) included patients treated with Exenatide, Dulaglutide, Liraglutide, Semaglutide, Tirzepatide, or Lixisenatide, while the comparator cohort without GLP-1 RA use (n = 57,788) included patients not receiving these therapies. Propensity score matching (PSM) was conducted to adjust for baseline differences, including demographics (age, sex, ethnicity), comorbidities (hypertension, diabetes, obesity, smoking), and medication use (statins, insulin, corticosteroids, SGLT2 inhibitors, methotrexate, rituximab)...Comorbidities such as hypertension (73.6% vs. 25.8%), diabetes (71.1% vs. 14.4%), and obesity were more prevalent, and medication use, including aspirin (44.2%) and metformin (56.8%), was also higher... GLP-1 RA is associated with significant reductions in mortality and cardiovascular events in patients with inflammatory myositis and necrotizing myopathy. These findings suggest that GLP-1 RAs may be a valuable adjunctive therapy for..."

Retrospective data • Cardiovascular • Dermatomyositis • Diabetes • Genetic Disorders • Hypertension • Immunology • Inflammation • Metabolic Disorders • Myocardial Infarction • Myositis • Obesity • Venous Thromboembolism

Risk of Hearing Loss in Patients Treated with Exendin-4 Derivatives: A Network Meta-Analysis of Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors. (PubMed, Pharmaceuticals (Basel)) - " This comprehensive NMA identifies a significant association between exendin-4 derivatives (lixisenatide and efpeglenatide) and potential ototoxicity. Clinicians should carefully consider this potential ototoxicity when prescribing exendin-4 derivatives, particularly in patients with pre-existing hearing loss risk factors."

Journal • Retrospective data • Review • Otorhinolaryngology

Antidiabetic GLP-1 Receptor Agonists Have Neuroprotective Properties in Experimental Animal Models of Alzheimer's Disease. (PubMed, Pharmaceuticals (Basel)) - "Ameliorated amyloid-β plaque and neurofibrillary tangle formation and deposition following exenatide, liraglutide, and lixisenatide treatment was confirmed in several models. Finally, restoration of cognitive functions, particularly spatial memory, was also observed for semaglutide and dulaglutide. GLP-1RAs, therefore, hold promising disease-modifying potential in the management of AD."

Journal • Preclinical • Review • Alzheimer's Disease • CNS Disorders • Inflammation • GSK3B • IRS1 • MAPK8

Association of Glucagon-Like Peptide-1 Agonists and Mortality Among Patients With Idiopathic Pulmonary Fibrosis (ATS 2025) - "We included patients older than 18 years with a diagnosis of IPF (ICD-10 J84.112) and stratified the data according to GLP-1 agonist use, including liraglutide, lixisenatide, tirzepatide, dulaglutide, exenatide, and semaglutide...Notably, less than 7.5% of these patients were on antifibrotics, including pirfenidone or nintedanib...However, the infrequent use of antifibrotics in this analysis raises questions about their underutilization. Further prospective research is needed to better understand GLP-1 agosnists role in patients with IPF."

Clinical • Atherosclerosis • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Genetic Disorders • Heart Failure • Hypertension • Idiopathic Pulmonary Fibrosis • Immunology • Metabolic Disorders • Nephrology • Obesity • Pulmonary Disease • Renal Disease • Respiratory Diseases • Type 2 Diabetes Mellitus

GLP1 RECEPTOR AGONISTS AND HEPATIC DECOMPENSATION IN PATIENTS WITH MASH CIRRHOSIS: A PROPENSITY-MATCHED ANALYSIS OF THE US COLLABORATIVE NETWORK (DDW 2025) - "We constructed 1-1 propensity-score (PS)-matched cohorts of patients initiating GLP-1RAs (semaglutide, liraglutide, exenatide, dulaglutide, albiglutide, tirzepatide, or lixisenatide) or DPP-4 inhibitors (alogliptin, linagliptin, saxagliptin or sitagliptin). In patients with compensated MASH cirrhosis, GLP-1RAs were associated with significantly lower rates of hepatic decompensation and all-cause mortality compared to DPP-4 inhibitors. These findings suggest a potential therapeutic benefit of GLP-1RAs in this population, warranting further validation through prospective studies."

Clinical • CNS Disorders • Diabetes • Fibrosis • Genetic Disorders • Hematological Disorders • Hepatic Encephalopathy • Hepatocellular Cancer • Hepatology • Immunology • Liver Failure • Metabolic Dysfunction-Associated Steatohepatitis • Nephrology • Obesity • Oncology • Renal Disease • Solid Tumor

Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System. (PubMed, Sci Rep) - "We conducted a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database (2005 Q2-2024 Q3) to evaluate neurological adverse events (NAEs) associated with six glucagon-like peptide-1 receptor agonists (GLP-1 RAs): exenatide, liraglutide, lixisenatide, dulaglutide, semaglutide, and tirzepatide. While these pharmacovigilance findings underscore the need for heightened clinical vigilance, they represent associations rather than causal relationships, constrained by inherent limitations of FAERS such as reporting bias and confounding. Future prospective studies are needed to confirm these associations and clarify underlying mechanisms."

Adverse events • Journal • Diabetes • Metabolic Disorders • Movement Disorders

Disparities in GLP-1 receptor agonist prescriptions among breast cancer survivors with type 2 diabetes. (ASCO 2025) - "The primary outcome was the rate of GLP-1RA prescription (lixisenatide, albiglutide, dulaglutide, semaglutide, liraglutide, exenatide, tirzepatide). Significant disparities in GLP-1RA prescription rates were identified among breast cancer survivors with DM2, particularly among older adults and non-White racial groups. This emphasizes the need for targeted interventions to improve equitable access to these classes of pharmaceutics with important health benefits in cancer survivors. Table 1: GLP-1RA Prescription Disparities by Racial Subgroups"

Breast Cancer • Coronary Artery Disease • Diabetes • Dyslipidemia • Endocrine Cancer • Gastrointestinal Disorder • Genetic Disorders • Heart Failure • Hypertension • Metabolic Disorders • Obesity • Obstructive Sleep Apnea • Oncology • Pancreatic Cancer • Pancreatitis • Respiratory Diseases • Sleep Disorder • Solid Tumor • Thyroid Gland Carcinoma • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges. (PubMed, Pharmacol Res) - "To date, clinical trials have shown that three GRA, exenatide, liraglutide and lixisenatide can improve motor deficits as an add-on therapy in PD patients and liraglutide can improve cognitive function in AD patients. The dual GLP-1/gastric inhibitory polypeptide (GIP) receptor agonists have been demonstrated to have beneficial effects in AD and PD mice models. Overall, GRA are highly promising novel drugs, but future clinical studies should identify which subsets of patients should be targeted as potential candidates for their symptomatic and/or neuroprotective benefits, investigate whether combinations with other classes of drugs can further augment their efficacy, and evaluate their long-term disease-modifying and adverse effects."

Journal • Review • Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders • Diabetes • Genetic Disorders • Huntington's Disease • Inflammation • Metabolic Disorders • Movement Disorders • Obesity • Parkinson's Disease • Type 2 Diabetes Mellitus

ADVERSE EVENTS OF PANCREATITIS ASSOCIATION TO VARIOUS GLP-1 RECEPTOR AGONIST: ANALYSIS PER US FDA ADVERSE REPORTING SYSTEM (DDW 2025) - "Lixisenatide has highest PRR 4.74 (CI 2.22-10.11, P <0.001). Among GLP-1 RA, there are differences in pancreatitis related AE PRR in FAERS. Higher association is found between with liraglutide and exenatide for pancreatitis, chronic pancreatitis and acute pancreatitis which is in line with earlier reports from clinical trial meta-analysis and real word AE assessments. Newer GLP-1 RA tirzepatide and dulaglutide, as per our assessment, are reported lower PRR and thus lower association signal with pancreatitis related AEs."

Adverse events • Gastrointestinal Disorder • Pancreatitis

ANALYSIS OF UPPER GASTROINTESTINAL ADVERSE EVENTS AMONG GLP-1 RECEPTOR AGONISTS REPORTED IN US FDA ADVERSE EVENT REPORTING SYSTEM: FOCUS ON GERD, PEPTIC ULCER AND HEMATEMESIS (DDW 2025) - "Results PRR for GERD AEs are higher in case of lixisenatide PRR 2.34 (CI 0.87-6.32, P =0.0926), semaglutide PRR 1.45 (CI 1.31-1.60, P <0.001) and liraglutide PRR 1.30 (CI 1.18-1.43, P <0.001)...PRR for peptic ulcer AEs are higher in case of semaglutide PRR 1.58 (CI 1.03-2.43, P =0.0352), liraglutide PRR 1.48 (CI 0.99-2.23, P =0.0580) and Exenatide PRR 1.46 (CI 1.07-1.99, P =0.0165)...Though in general similar AEs are seen within this class of drugs, this study indicates there might be different AE risks with different GLP-1 RA. Dulaglutide and Tirzepatide seem to have lower reports GERD and peptic ulcer related AEs."

Adverse events • Dyspepsia • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Peptic Ulcer

The LIXIPARK trial: lixisenatide to treat patients with early Parkinson disease (PD) (JSNE 2025) - No abstract available

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease

A Descriptive Analysis from VigiAccess on Drug-related Problems Associated with the Glucagon-like Peptide-1 Receptor Agonists. (PubMed, Curr Drug Saf) - "Qualified healthcare practitioners must educate the patients administering the GLP- 1 RAs to minimize preventable DRPs. Also, careful and frequent monitoring of GLP-1 RAs improves therapeutic outcomes by ruling out DRPs. Healthcare practitioners should comply with approved therapeutic guidelines to enhance the quality of GLP-1 RAs treatment."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Children and Adolescents: A Meta-Analysis of Randomized Controlled Trials (ESPE-ESE 2025) - "Until recently, the approved treatments for pediatric patients encompassed only metformin and insulin... We systematically searched PubMed, Embase, and Cochrane databases in December 2023 for randomized controlled trials (RCTs) that compared GLP-1 RA (exenatide, lixisenatide, dulaglutide, liraglutide or semaglutide) with placebo in patients from ages 8 to 19 years old, for the treatment of T2DM... In this meta-analysis, the use of GLP-1 RA in pediatric patients with T2DM yields significant reductions in HbA1c levels compared to placebo, indicating its potential as an effective adjunctive therapy. However, it’s noteworthy that there were non-significantly changes in fasting glucose concentration and reduction in BMI compared to placebo."

Late-breaking abstract • Retrospective data • Diabetes • Genetic Disorders • Hypoglycemia • Metabolic Disorders • Obesity • Pediatrics • Type 2 Diabetes Mellitus

DUAL GLP-1/GIP RECEPTOR AGONISTS THAT CAN CROSS THE BBB SHOW SUPERIOR NEUROPROTECTIVE EFFECTS (ADPD 2025) - "Methods Bydureon (exenatide) and Adlyxin (lixisenatide) showed disease-modifying protective effects in patients with PD in two phase 2 clinical trials...NLY01, a pegylated form of exenatide that can't cross the BBB did not show any effects in PD patients in a phase 2 trial...Results Currently, two phase 3 trials are ongoing, testing the diabetes drug Ozempic/Wegovy (semaglutide) in AD patients...In animal models of AD or PD, dual agonists were able to protect neurons better than GLP-1 class drugs such as liraglutide, semaglutide or tirzepatide that were designed to treat diabetes and that stay in the blood for longer periods. Conclusions The dual GLP-1/GIP receptor agonist KP405 (DA5-CH) is currently in a phase 1 clinical trial and Results will be shared at the conference."

Alzheimer's Disease • CNS Disorders • Diabetes • Inflammation • Metabolic Disorders • Movement Disorders • Parkinson's Disease

Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review. (PubMed, Neurol Ther) - " Preclinical studies indicate that select GLP-1 RAs are CNS penetrant; whether GLP-1 RAs reproducibly engage neural targets hypothesized to subserve dimensions of psychopathology (e.g., general cognitive functions) remains incompletely characterized."

Journal • Review • Alzheimer's Disease • CNS Disorders • Diabetes • Genetic Disorders • Metabolic Disorders • Movement Disorders • Obesity • Parkinson's Disease

Exploring Glucagon-Like Peptide-1 Receptor Agonists Usage Among Non-Diabetic Healthcare Providers: A Cross-Sectional Multi-Country Study. (PubMed, Health Sci Rep) - "Semaglutide (45.7%, 95% CI: 41.8%-49.5%) was the most commonly used GLP-1RA, followed by Liraglutide (36.9%, 95% CI: 33.2%-40.8%). Other GLP-1RAs were used less frequently, including Dulaglutide (17.0%, 95% CI: 14.2%-20.1%), Exenatide (14.1%, 95% CI: 11.5%-17.0%), Albiglutide (7.0%, 95% CI: 5.1%-9.2%), and Lixisenatide (8.5%, 95% CI: 6.5%-10.9%...This study provides the first prevalence estimate of GLP-1RA use among HCPs and GLP1-Ras users and explores the associations between demographic characteristics and perceptions of safety and efficacy. The findings highlight the self-prescribing practices of these medications for weight management and underscore the need for appropriate monitoring to avoid potential health risks."

Journal • Genetic Disorders • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy of Simplifying Complex Insulin Regimen on Glycometabolic Parameters and Target Organ Damage in Type 2 Diabetes: A Retrospective Cohort Study. (PubMed, J Diabetes Res) - "A protective role of FRCs in diabetic ASCVD has been proven, but their protective role in CKD was not observed. The significant improvements in glycemic and weight control, as well as in TODs, suggest that therapy simplification may represent a more favorable approach compared to the continuation of previous ICT even in patients characterized by high baseline TDD and HbA1c levels."

Journal • Retrospective data • Chronic Kidney Disease • Diabetes • Hypoglycemia • Metabolic Disorders • Nephrology • Pain • Renal Disease • Retinal Disorders • Type 2 Diabetes Mellitus

Efficacy and Safety of Tirzepatide Compared with GLP-1 RAs in Patients with Type 2 Diabetes Treated with Basal Insulin: A Network Meta-analysis. (PubMed, Diabetes Ther) - "Tirzepatide demonstrated statistically significantly greater reductions in HbA1c and body weight when compared with selected GLP-1 RAs and placebo in patients with T2DM treated with basal insulin. Overall, the safety profile of tirzepatide was similar to that of GLP-1RAs."

Journal • Retrospective data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

A Retrospective Comparative Analysis of Cutaneous Adverse Reactions in GLP-1 Agonist Therapies. (PubMed, J Drugs Dermatol) - "Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System, it was found that the 5 most common cutaneous reactions associated with GLP-1 agonists were eczematous, pruritus, drug eruptions, hyperhidrosis, and alopecia. 2025;24(4):413-415. doi:10.36849/JDD.8605."

Clinical • Retrospective data • Alopecia • Atopic Dermatitis • Dermatology • Diabetes • Genetic Disorders • Immunology • Metabolic Disorders • Obesity • Pruritus • Type 2 Diabetes Mellitus

Role of Glucagon-Like Peptide-1 on Amyloid, Tau, and α-Synuclein: Target Engagement and Rationale for the Development in Neurodegenerative Disorders. (PubMed, Neurosci Biobehav Rev) - "We observed that GLP-1 and GLP-1 RAs modulate molecular and cellular changes known to govern the phenomenology of neurodegenerative diseases. Future research should examine the interaction between signaling molecules, neuronal subpopulations, and cognitive effects affected by GLP-1 and GLP-1 RA administration."

Journal • Review • Alzheimer's Disease • CNS Disorders • Inflammation • Movement Disorders • Parkinson's Disease

Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data. (PubMed, Int J Impot Res) - "Reports from Q4 2003 to Q1 2024 were analyzed using the OpenVigil 2.1 platform to identify male patients experiencing orgasmic dysfunction, erectile dysfunction, or decreased libido linked to GLP-1 receptor agonists (tirzepatide, semaglutide, dulaglutide, exenatide, lixisenatide, and liraglutide). Despite statistically significant chi-squared values (P < 0.0001), low ROR (0.41, 95% Confidence interval (CI): 0.36-0.48), PRR (0.41, 95% CI: 0.36-0.48), and RRR (0.42, 95% CI: 0.36-0.48) suggest a weak association. These findings underscore the need for monitoring as GLP-1 use expands, though overall patient risk remains low."

Journal • Diabetes • Erectile Dysfunction • Metabolic Disorders • Sexual Disorders • Type 2 Diabetes Mellitus

Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials. (PubMed, Diabetes Obes Metab) - "The magnitude of efficacy for intended therapeutic actions (HbA1c and body weight reduction) varied widely between incretin mimetic glucose-lowering agents. However, larger therapeutic efficacy was not systematically associated with higher GI AE or drug discontinuation rates, indicating better tolerability of the more effective agents/preparations."

Clinical • Journal • Diabetes • Gastrointestinal Disorder • Metabolic Disorders • Type 2 Diabetes Mellitus

Are glucagon-like peptide-1 analogs better answer for obese patients with metabolic dysfunction associated steatotic liver disease than bariatric surgery? Real-world evidence (EASL 2025) - "Primary outcomes were the development of decompensated cirrhosis and all-cause mortality in patients treated with GLP-1 analogs (semaglutide, tirzepatide, dulaglutide, exenatide, lixisenatide) compared to patients treated with bariatric surgery (gastric bypass, sleeve gastrectomy, biliopancreatic diversion with duodenal switch, vertical band gastroplasty)... Out of 545,931 patients with MASLD, 73,339 (13.44%, median 733 days) patients were treated with GLP1 analog, 38,541 (7.06%, median 690 days) sodium-glucose cotransporter 2 (SGLT 2) inhibitors and 29,917 (5.48%, median 832 days) received other weight loss medications (naltrexone, topiramate or phentermine)... GLP-1 analogs are increasingly being used in patients with MASLD. GLP-1 analogs and bariatric surgery reduce the risk of decompensated cirrhosis in obese patients with MASLD. Our results indicate that patients with MASLD treated with GLP-1 analogs have a lower risk of decompensated cirrhosis and better overall..."

Bariatric surgery • Clinical • HEOR • Real-world • Real-world evidence • Surgery • Fibrosis • Gastrointestinal Disorder • Genetic Disorders • Hepatocellular Cancer • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Obstructive Sleep Apnea • Oncology • Respiratory Diseases • Sleep Apnea • Sleep Disorder • Solid Tumor

THE LIXIPARK TRIAL, A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, STUDY OF LIXISENATIDE IN PATIENTS WITH EARLY PARKINSON'S DISEASE (PD) (ADPD 2025) - "Secondary endpoints included: (a) mean changes from baseline in MDS-UPDRS I and II in ON (month-12), and levodopa equivalent daily dosage (LEDD) (month-12); (b) mean MDS-UPDRS III score in the practically defined OFF condition at month-14 (end of wash-out) and (c) safety and tolerability. Conclusions Lixisenatide had beneficial effects on motor progression in patients with early PD, supporting a disease-modifying effect warranting further investigations and comparisons with other GLP1 agonists currently under assessment for neuroprotection PD."

Clinical • CNS Disorders • Diabetes • Metabolic Disorders • Movement Disorders • Parkinson's Disease • Type 2 Diabetes Mellitus

Neuroprotective effects of lixisenatide against propagation of α-synuclein pathology in Parkinson's disease. (PubMed, Neural Regen Res) - "In addition, lixisenatide inhibited α-synuclein phosphorylation and seeding between neurons, mediated by neuronal lymphocyte-activation gene 3 expression. This study provides new insights into the mechanism underlying the disease-modifying effects of glucagon-like peptide-1 receptor agonists in the treatment of Parkinson's disease."

Journal • CNS Disorders • Diabetes • Metabolic Disorders • Movement Disorders • Parkinson's Disease • Type 2 Diabetes Mellitus • LAG3